Astrazeneca Plc · LSE:AZN
Astrazeneca — Meet AZN management: ASCO 2019
10 slides from Astrazeneca's conference presentation, Jun 3, 2019
Slide 1: Meet AZN management: ASCO 2019 Breakout 2: late-stage pipeline
Marquis_CONFERENCE AZ2019 Meet AZN management: ASCO 2019 Breakout 2: late-stage pipeline Klaus Edvardsen, Senior Vice President, Oncology R&D, late stage 3 June 2019
Slide 2: Forward-looking statements
Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act 1995, we are providing the following cautionary statement: this document contains certain forward-looking statements with respect to the operations, pe
Slide 3: Lynparza: ovarian cancer
Lynparza: ovarian cancer Leading development programme across lines of treatment Study 19: overall survival SOLO-2: progression-free PAOLA-1: 1st-line in ‘all-comer’ 3rd-line+ patients survival in BRACm 2nd line ‘all-comer’ ovarian cancer 1L (complete response; partial response; or non-evidence of d
Slide 4: Lynparza: pancreatic and prostate cancers
Lynparza: pancreatic and prostate cancers Extending benefit of PARP inhibition1 into new cancer types POLO: first positive Phase III PROfound: Phase III in mCRPC2 PROpel: Phase III combination trial of a PARPi in gBRCAm HRRm3 (post abiraterone of Lynparza and abiraterone in metastatic pancreatic can
Slide 5: Breast cancer: Lynparza and capivasertib
Breast cancer: Lynparza and capivasertib Going into early disease and new mode of action OlympiAD: first PARP inhibitor OlympiA: gBRCAm Capivasertib (AZD5363): novel, approved in the EU for patients adjuvant breast cancer oral selective AKT inhibitor with gBRCAm HER2-negative Potential in breast, pr
Slide 6: Tagrisso: non-small cell lung cancer
Tagrisso: non-small cell lung cancer Focus on early-stage disease and resistance ADAURA: adjuvant SAVANNAH: EGFRm, MET+ ORCHARD: identifying EGFRm1 NSCLC2 locally-advanced/metastatic resistance / progression factors NSCLC Stratification: Stage (Ib vs. II vs. IIIa); Patients with NSCLC who pro- Scree
Slide 7: Imfinzi: standard of care in unresectable, Stage III NSCLC
Imfinzi: standard of care in unresectable, Stage III NSCLC Differentially investing to focus on early-stage disease Unprecedented 11.2 months >50% of patients receiving Early-stage NSCLC trials improvement in median Imfinzi were alive at 36 months progression-free survival Name Phase Population Data
Slide 8: Late-stage Immuno-Oncology strategy
Late-stage Immuno-Oncology strategy Major ongoing late-stage Phase III trials Replace Create a new treatment paradigm for patients that replaces CTx Add Generate additional benefits for patients through additive or combination treatment with CTx Early Provide earlier treatment for patients and repla
Slide 9: Q&A
Q&A
Slide 10: Use of AstraZeneca conference call, webcast and presentation slides
Use of AstraZeneca conference call, webcast and presentation slides The AstraZeneca webcast, conference call and presentation slides (together the ‘AstraZeneca Materials’) are for your personal, non- commercial use only. You may not copy, reproduce, republish, post, broadcast, transmit, make availab